Clinical trial
A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.
NCT06158152 is registered in ClinicalTrials.gov with Industrial Farmacéutica Cantabria, S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.
- Lead sponsor
- Industrial Farmacéutica Cantabria, S.A.
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- May 20, 2024
- Completion date
- March 1, 2026
- Enrollment
- 48 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.